Pharming Group N.V. and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program”
Pharming Group N.V in association with HAEi, the international umbrella organization for the world’s Hereditary Angioedema (HAE) patient groups, announce the appointment of Inceptua Medicines Access as their new distribution partner for the “HAEi Global Access Program” (HAEi GAP).
This enables patients in all countries where Pharming’s product RUCONEST® is not commercially available to gain access to the drug through an ethical and regulatory compliant mechanism. It is the only known program of this type which has been initiated through a patient group.
“HAEi exists to support patients with HAE gain access to HAE therapies to improve their quality of life and potentially be life-saving in the case of a laryngeal attack,”- Henrik Balle Boysen, HAEi Executive Director